Isentress (Raltegravir Chewable Tablets) and Pamprin Cramp Formula

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Oral products that contain aluminum or magnesium can interfere with the absorption of raltegravir, even if they are not taken at the same time. This may reduce the blood levels of raltegravir, which may make the medication less effective in treating HIV infection. You should avoid taking aluminum- or magnesium-containing products regularly or for a prolonged duration during treatment with raltegravir. Talk to a healthcare professional if you are not sure whether a product contains something that could potentially interact with your medication or if you have questions on how to take this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with aluminum- and magnesium-containing antacids has been shown to reduce the oral bioavailability of raltegravir. The proposed mechanism is chelation of raltegravir by polyvalent cations, but changes in solubility and lipophilicity of raltegravir related to pH increases may also contribute. In drug interaction studies, raltegravir peak plasma concentration (Cmax), systemic exposure (AUC) and trough plasma concentration (Cmin) decreased by 44%, 49% and 63%, respectively, when a single 20 mL dose of aluminum and magnesium hydroxide antacid was administered simultaneously with raltegravir (400 mg twice daily). The Cmax, AUC and Cmin of raltegravir decreased by 51%, 51% and 56%, respectively, when the antacid was given 2 hours before raltegravir, and by 22%, 30% and 57%, respectively, when the antacid was given 2 hours after raltegravir. When given 4 hours apart, raltegravir Cmax, AUC and Cmin decreased by 22%, 19% and 60% with antacid administered first, and by 30%, 32% and 62% with raltegravir administered first. Minimal changes in raltegravir Cmax and AUC were observed when administration was staggered by 6 hours; however Cmin was still diminished by approximately 50% regardless of whether antacid was administered before or after raltegravir. When given with a single dose of antacid containing calcium carbonate 3000 mg, raltegravir Cmax, AUC and Cmin decreased by 52%, 55% and 32%, respectively. These changes are not considered clinically significant by the manufacturer.

MANAGEMENT: It is not known to what extent non-antacid aluminum and magnesium salts may interact with raltegravir. Until more information is available, it may be advisable to avoid taking raltegravir with any aluminum- and/or magnesium-containing product. According to the manufacturer, antacids containing calcium carbonate may be used without dose adjustment for raltegravir.

Isentress (Raltegravir Chewable Tablets)

Generic Name: raltegravir

Brand name: Isentress, Isentress HD

Synonyms: Isentress

What is Isentress (Raltegravir Chewable Tablets)?

Pamprin Cramp Formula

Generic Name: acetaminophen / magnesium salicylate / pamabrom

Brand name: Pamprin Cramp Formula

Synonyms: n.a.

What is Pamprin Cramp Formula?